期刊文献+

慢性乙肝患者脯氨酸肽酶与肝纤维化的关系分析

The relationship between prolidase and liver fibrosis in chronic hepatitis B patients
下载PDF
导出
摘要 目的了解血清脯氨酸肽酶(prolidase,PLD)与乙型病毒性肝炎肝纤维化程度的关系。方法测定191例乙型肝炎患者血清中PLD水平,利用ROC曲线分析ALT、AST、AST/ALT和PLD的面积,判断PLD的最优截断点并计算不同标准的灵敏度、特异度、阳性预测值(PPV)、阴性预测值(NPV)、Youden指数。结果慢性乙型肝炎患者PLD值随着肝纤维化严重程度升高,S2-4期(明显肝纤维化)明显高于S0-1期(无明显肝纤维化)(P<0.01)。ALT、AST、AST/ALT和PLD的ROC曲线下面积分别为0.614、0.648、0.655和0.807。PLD的最优截断点约为1 250 U/L,灵敏度和特异度分别为75.6%和75.2%。结论血清PLD测定对于慢性乙型肝炎患者肝纤维化程度判定有一定的临床价值。 Objective To study the relationship between prolidase (PLD) and liver fibrosis in chronic hepatitis B patients. Methods PLD activity in serum collected from 191 patients with hepatitis B were determined. Receiver operating characteristic curve (ROC) was used to evaluate diagnostic value of PLD activity. Results PLD values of hepatitis B patients rose with liver fibrosis severity, and PLD value of S2-4 phases was higher than that of S0.1 phases (P 〈0.01 ). The AUROC of ALT, AST, AST/ALT and PLD were 0. 614, 0. 648, 0. 655 and 0. 807, respectively. The optimal cutoff value of PLD was 1 250 U/L. Sensitivity and specificity were 75.6% and 75.2% , respectively. Conclusion PLD is a potent marker for assessing liver fibrosis stages in chronic hepatitis B patients.
作者 程大也
出处 《胃肠病学和肝病学杂志》 CAS 2009年第12期1114-1116,共3页 Chinese Journal of Gastroenterology and Hepatology
基金 辽宁省教育厅2008年度高等学校科研项目基金资助(2008752)
关键词 慢性乙型肝炎 脯氨酸肽酶 肝纤维化 Chronic hepatitis B Prolidase Liver fibrosis
  • 相关文献

参考文献2

二级参考文献25

  • 1张文胜,王宝恩,王泰龄,欧晓娟,陈煜,李琴,王小明,钱林学,马红,贾继东.慢性乙型肝炎肝纤维化无创性诊断模型的建立[J].中华肝脏病杂志,2006,14(3):169-173. 被引量:81
  • 2曾民德,陆伦根,茅益民.肝纤维化的诊断方法及其评估(上)[J].肝脏,2006,11(2):102-105. 被引量:15
  • 3Mchutchison J, Poynard T, Afdhal N, et al. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibro- sis group. Clin Gastroenterol Hepatol, 2006, 4: 1214-1220.
  • 4Rockey DC, Bissell M. Noninvasive measures of liver fibrosis. Hepatology, 2006, 43: s113-120.
  • 5Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology, 2007, 45: 242-249.
  • 6Powell EE, Edwards-Smith C J, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000,31: 828-833.
  • 7Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology, 2006, 130: 1679-1687.
  • 8Guha IN, Parkes J, Roderick PR, et al. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut, 2006, 55: 1650-1660.
  • 9Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology, 2007, 46:582-589.
  • 10Metwally MA, Zein Co, Zein NN. Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci, 2007, 52: 582-588.

共引文献405

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部